CERENOME, INC. 10-Q

Item 5. Other Information None. 22 Item 6. Exhibits EXHIBIT INDEX PLUS THERAPEUTICS, INC. Exhibit Number Exhibit Title Filed with this Form 10-Q Incorporated by Reference Form File No. Date Filed 3.1 Composite Certificate of Incorporat ion . 10-K 001-34375 Exhibit 3.1 03/11/2016 3.2 Certificate of Amendment to Amended and Restated Certificate of Incorporation. 8-K 001-34375 Exhibit 3.1 05/10/2016 3.3 Certificate of Amendment to Amended and Restated Certificate of Incorporation . 8-K 001-34375 Exhibit 3.1 05/23/2018 3.4 Certificate of Amendment to Amended and Restated Certificate of Incorporation . 8-K 001-34375 Exhibit 3.1 07/29/2019 3.5 Certificate of Amendment to Amended and Restated Certificate of Incorporation . 8-K 001-34375 Exhibit 3.1 08/06/2019 3.6 Certificate of Designation of Preferences, Rights and Limitations of Series A 3.6% Convertible Preferred Stock . 8-K 001-34375 Exhibit 3.1 10/08/2014 3.7 Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock . 8-K 001-34375 Exhibit 3.1 11/28/2017 3.8 Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock . 8-K 001-34375 Exhibit 3.1 07/25/2018 3.9 Amended and Restated Bylaws of Plus Therapeutics, Inc. 8-K 001-34375 Exhibit 3.2 07/29/2019 4.1 Description of Securities . 10-K 001-34375 Exhibit 4.1 03/30/2020 4.2 Form of Common Stock Certificate . 10-K 001-34375 Exhibit 4.33 03/09/2018 4.3 Form of Series U Warrant . S-1/A 333-229485 Exhibit 4.37 09/16/2019 4.4 Form of Warrant Amendment Agreement 8-K 001-34375 Exhibit 4.1 04/23/2020 4.5 Form of Underwriters’ Warrant Amendment Agreement 8-K 011-34375 Exhibit 4.1 10/05/2020 10.1** Master Services Agreement between Piramal Pharma Solutions, Inc. and Plus Therapeutics, Inc. 10-K 001-334275 Exhibit 10.24 02/22/2021 31.1 Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1* Certifications Pursuant to 18 U.S.C. Section 1350/ Securities Exchange Act Rule 13a-14(b), as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002 X 101.INS XBRL Instance Document X 23 101.SCH XBRL Schema Document X 101.CAL XBRL Calculation Linkbase Document X 101.DEF XBRL Definition Linkbase Document X 101.LAB XBRL Label Linkbase Document X 101.PRE XBRL Presentation Linkbase Document X * In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No. 34‑47986, the certifications furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10‑Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 except to the extent that the Company specifically incorporates it by reference. ** Portions of the exhibit (indicated by asterisks) have been omitted. 24 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick Dated: April 22, 2021 Marc H. Hedrick President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) By: /s/ Andrew Sims Dated: April 22, 2021 Andrew Sims Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer) 25